Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study
Cardiovascular Therapeutics · 2026
DOI: 10.1155/cdr/5113761 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiovascular Therapeutics, 2026. Verfasst von Jie Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Atrial Fibrillation, Diabetes Mellitus, Type 2, Cardiomyopathy, Dilated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Projects of Shaanxi Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Dilated cardiomyopathy (DCM) is characterized by left ventricular dilation and systolic dysfunction in the absence of severe hypertension, valvular disease, or coronary artery disease. Patients with DCM have a high risk of atrial fibrillation (AF), especially when combined with Type 2 diabetes mellitus (T2DM). Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have shown cardioprotective effects in patients with diabetes, suggesting potential benefits in reducing AF incidence.
Methods
We retrospectively analyzed clinical data from patients with T2DM diagnosed with DCM treated at the First Affiliated Hospital of Xi’an Jiaotong University between January 2018 and January 2024. Patients were divided into two groups based on their use of SGLT2i. The incidence of AF was compared between these groups using logistic regression models adjusted for potential confounders, including demographic characteristics, comorbidities, and medication history. Additionally, a subgroup analysis was conducted to evaluate the relationship between AF and SGLT2i.
Results
Among 455 enrolled patients, 95 (20.9%) were treated with SGLT2i. The incidence of AF was significantly lower in the SGLT2i group compared with the control group (7/95 [7.4%] vs. 68/360 [18.9%]; OR = 0.308, 95 % CI = 0.132–0.735, p = 0.008). Subgroup analyses showed consistent results across various age, gender, hypertension status, and diabetes duration groups, indicating the robustness of the association between SGLT2i use and reduced AF incidence.
Conclusion
Our study suggests that SGLT2i use is associated with a lower incidence of AF in patients with T2DM and DCM. This observed association warrants further investigation in prospective studies to elucidate its nature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn.
- Department of Health Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn.
- Department of Cardiovascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, xjtu.edu.cn.
ORCID-Profile: Jie Wang, Shanshan Qi, Siyuan Chen, Hang Yu
Förderung
- Key Research and Development Projects of Shaanxi Province
Zitieren
APA
Wang, J., Qi, S., Chen, S., & Yu, H. (2026). Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/5113761
Vancouver
Wang J, Qi S, Chen S, Yu H. Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study. Cardiovascular Therapeutics. 2026. doi:10.1155/cdr/5113761
BibTeX
@article{Wang2026,
author = {Wang, Jie and Qi, Shanshan and Chen, Siyuan and Yu, Hang},
title = {Effect of SGLT2 Inhibitors on Atrial Fibrillation in Patients With Type 2 Diabetes With Dilated Cardiomyopathy: A Cohort Study},
journal = {Cardiovascular Therapeutics},
year = {2026},
doi = {10.1155/cdr/5113761}
}
EUVIMED